Every report comes from a Lived member, sent anonymously.
Have you tried Dupixent (Dupilumab) for Eczema?
Dupilumab, sold as Dupixent, is an injected prescription medicine for several long-term conditions that share the same kind of allergic inflammation. It is a biologic, meaning a lab-made antibody, rather than a steroid. Its best-known use is moderate-to-severe eczema (atopic dermatitis) in adults and children 6 months and older whose eczema is not adequately controlled by prescription creams and ointments, or who cannot use them. It can be used with or without steroid creams. It is also approved as an add-on maintenance treatment, taken alongside a person's usual medicines, for moderate-to-severe asthma in people 6 and older when the asthma is the eosinophilic type (marked by high levels of eosinophils, a kind of white blood cell) or depends on steroid pills; for uncontrolled chronic sinus inflammation with nasal polyps in people 12 and older; and for uncontrolled COPD (chronic obstructive pulmonary disease) with raised eosinophils in adults. Other approved uses are eosinophilic esophagitis, an allergic inflammation of the food pipe, in people 1 year and older who weigh at least 15 kg (about 33 pounds); prurigo nodularis, a condition of intensely itchy skin bumps, in adults; chronic spontaneous urticaria, hives that keep returning without a known trigger, in people 2 and older who still have symptoms despite antihistamines; bullous pemphigoid, a blistering skin disease, in adults, together with a tapering course of steroid pills; and allergic fungal rhinosinusitis, a form of chronic sinus inflammation, in people 6 and older who have already had sinus surgery.
Many of the conditions Dupixent treats are driven in part by two immune signaling proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13). These messengers act on many of the cells involved in allergic inflammation, including eosinophils and mast cells, and help trigger the release of other inflammatory chemicals and of IgE, the antibody behind many allergic reactions. Dupilumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds to a receptor component that IL-4 and IL-13 both use, so it blocks the signals of both. Turning down this pathway reduces the inflammation behind symptoms such as itchy eczema, asthma flare-ups and nasal polyps. Exactly how this produces each benefit has not been fully worked out, and the medicine helps most when this type of inflammation is a main driver of a person's disease.
Dupixent is injected under the skin with a prefilled pen or a prefilled syringe. After training from the care team, most people inject it at home, or a caregiver does it for them. The pen is approved for ages 2 and older and the syringe for ages 6 months and older. Teenagers 12 and older can inject themselves with an adult supervising, and children under 12 have injections given by a caregiver. How often it is given depends on the condition, age and, for children, body weight. Many adults inject once every 2 weeks, often after a larger first dose given as two injections at different sites. Some children inject every 4 weeks, and people with eosinophilic esophagitis who weigh 40 kg (about 88 pounds) or more inject every week. The prescription sets the exact schedule, so it should not be copied from someone treated for a different condition. Injections go into the thigh or belly, avoiding about 2 inches around the belly button, or into the upper arm if someone else gives the injection. Rotate the site each time and avoid skin that is tender, bruised, damaged or scarred. Dupixent is kept in the refrigerator and should warm to room temperature before use (30 to 45 minutes, depending on the dose) with the needle cap left on. If needed it can stay at room temperature for up to 14 days, after which it must be thrown away. It should not be frozen, shaken or left in heat or direct sunlight. If an every-2-week or every-4-week dose is missed, inject it within 7 days and continue the original schedule; after 7 days, inject it and start a new schedule from that date. A missed weekly dose is given as soon as possible, with the weekly schedule restarting from that day.
The most common side effects are reactions where the needle went in (redness, swelling or itching), eye irritation, and cold sores or other herpes virus flare-ups. Depending on the condition being treated, some people also notice sore throat, cold-like symptoms, joint pain or trouble sleeping, and blood tests may show a rise in eosinophils. Eye problems deserve particular attention, especially for people treated for eczema. Pink eye (conjunctivitis), inflammation of the clear front surface of the eye (keratitis) and eyelid inflammation (blepharitis) were more common with Dupixent than with placebo in eczema trials. Most cases cleared up, but rare cases have led to lasting vision problems. Tell the prescriber right away about new or worsening eye pain, redness, itching or blurred vision, since an eye specialist may need to examine you. People with significant dry eye or past eyelid or tear-duct surgery should mention it before starting. New joint pain, occasionally bad enough to make walking difficult, and new psoriasis (patches of thick, scaly skin) have also been reported. Both are worth reporting; some cases settle while treatment continues, and others lead to stopping the medicine. Serious allergic reactions are uncommon. Stop using Dupixent and get emergency help right away for trouble breathing or wheezing, swelling of the face, lips, tongue or throat, fainting or feeling faint, or widespread hives. Contact the prescriber right away about fever with swollen glands or joint pain, or a new rash such as bull's-eye-shaped spots, painful red lumps under the skin or red pus-filled spots, which can signal a delayed allergic reaction.
Dupixent is not a rescue medicine. It does not relieve a sudden asthma or COPD attack, so a rescue inhaler is still needed, and asthma or COPD that stays uncontrolled or gets worse after starting it should be discussed with the care team. Do not stop or cut back steroid pills, inhalers or creams on your own when Dupixent starts. Any reduction should be gradual and supervised, because stopping steroids quickly can cause withdrawal symptoms and can bring back conditions the steroids had been keeping under control. People who also have asthma should not change their asthma treatment without talking to their clinician. Rarely, people with asthma taking Dupixent have developed eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis (EGPA), an inflammation of blood vessels, sometimes while their steroid pill dose was being lowered. Contact the prescriber right away about a new rash, worsening shortness of breath, a fever that will not go away, chest pain, dark or brown urine, or numbness or pins and needles in the arms or legs. Live vaccines should be avoided during treatment, so it helps to get up to date on recommended vaccines before starting, and to tell anyone vaccinating you that you take Dupixent. A known parasitic worm infection should be treated before starting. People who have had an allergic reaction to dupilumab or its ingredients should not use it. For pregnancy, reports so far have not shown a medicine-related increase in birth defects or miscarriage, although the antibody likely reaches the baby, especially late in pregnancy. Poorly controlled asthma carries its own pregnancy risks. There is no information yet on dupilumab in breast milk. Anyone pregnant, planning a pregnancy or breastfeeding should weigh the choice with their clinician.
Dupixent is a long-term maintenance treatment, and improvement builds over weeks to months. In the main adult eczema trials, after 16 weeks about 36 to 39 percent of people taking it had clear or almost clear skin, compared with about 9 to 12 percent on placebo. Itch improved meaningfully (by at least 4 points on a 0 to 10 scale) in roughly 4 in 10 people taking Dupixent alone, compared with about 1 in 10 on placebo. Many people improve a great deal without their skin fully clearing, and response is not fixed at 16 weeks: in a year-long trial, about half of early responders were still clear or almost clear at one year, while some people who had not responded by week 16 responded later. In asthma, the main benefit is fewer serious flare-ups. In a large trial, severe asthma attacks happened about half as often as with placebo. The benefit was larger in people with higher blood eosinophil counts or higher FeNO (fractional exhaled nitric oxide, a breath test of airway inflammation), and people with low levels of both did no better than with placebo. This is why clinicians look at these markers when deciding whether Dupixent fits a person's asthma. Follow-up visits check whether the condition has improved enough to make continuing worthwhile, whether other medicines such as steroids can safely be reduced, and whether any eye, joint or skin problems have appeared.
Last reviewed • Oct 2026
Educational content, not medical advice.
I got this medication by jumping through several hoops via my dermatologist. Did anyone else but me ask about why they thought it might work? I discovered type 2 inflammatory diseases this way, and it frustrated me that my doc didn't inform me that asthma is comorbid in the same many other ailments are.